Methylergometrine is a semi‑synthetic ergot alkaloid and a potent oxytocic agent. It is used in obstetrics to prevent and control excessive bleeding after childbirth (postpartum haemorrhage) and following miscarriage or abortion. The medicine works by stimulating the smooth muscle of the uterus to contract, which compresses blood vessels and reduces blood loss. Administration is usually by injection (intramuscular or intravenous) and sometimes orally, but always under strict medical supervision in a hospital setting.

Methylergometrine belongs to the class of medications known as ergot alkaloids. Its primary pharmacological action is to induce rapid, sustained, and forceful contractions of the uterine smooth muscle.

In a normal delivery, the uterus contracts to expel the placenta and then continues to contract to compress the open blood vessels where the placenta was attached. If the uterus is "atonic" (weak or lacking tone), it cannot contract sufficiently, leading to potentially life-threatening haemorrhage. Methylergometrine acts directly on the smooth muscle of the uterus, increasing the tone, rate, and amplitude of rhythmic contractions. This effectively "clamps down" the uterus, significantly reducing the volume of blood lost.

While it is most active on the uterus, it also possesses moderate vasoconstrictive properties, meaning it can cause blood vessels to narrow. Because of this, it is generally used only after the delivery of the baby and the placenta is complete. It is not used to induce labour or during the first and second stages of labour, as its powerful contractions could harm the baby or cause uterine rupture. When administered by injection, its onset of action is very rapid, providing immediate clinical assistance during obstetric emergencies. Safe and effective use depends on following medical advice closely and limiting treatment to the recommended duration.

Methylergometrine may be indicated by your doctor for:

Postpartum Haemorrhage (PPH)

Prevention and treatment of excessive bleeding following the delivery of a baby.

Uterine Atony

Management of a "soft" or weak uterus that fails to contract after childbirth.

Post-Abortion Bleeding

Control of haemorrhage following a miscarriage or a surgical/medical abortion.

Routine Management of the Third Stage of Labour

Often used as part of active management to ensure the placenta is delivered safely and blood loss is minimised.

Methylergometrine may provide benefits such as:

• Rapid control of bleeding, which is crucial in preventing maternal morbidity and mortality during delivery.

• Strong uterine stimulation, providing a more sustained contraction than some other oxytocic medications.

• Effective prevention of excessive blood loss in high-risk patients.

• Versatile administration, allowing for immediate emergency use (injection) or follow-up care (tablets).

• Proven clinical track record in the management of obstetric complications.

While highly effective, Methylergometrine can cause side effects due to its systemic effects on smooth muscle.

Common side effects of Methylergometrine may include:

• Nausea and vomiting

• Abdominal pain (uterine cramping)

• Headache

• Dizziness

• High blood pressure (hypertension)

Uncommon side effects of Methylergometrine may include:

• Chest pain (angina)

• Palpitations or slow heart rate (bradycardia)

• Shortness of breath

• Skin rash or sweating

• Leg cramps

Serious side effects that may require immediate medical attention include:

• Severe Hypertension: Sudden, extreme rise in blood pressure leading to seizures or "stroke-like" symptoms.

• Ergotism: Intense vasoconstriction leading to coldness, numbness, or tingling in the fingers and toes.

• Myocardial Infarction: Chest tightness or pain that may indicate heart strain.

• Anaphylaxis: Severe allergic reaction with swelling and difficulty breathing.

Always consult your doctor if you notice any unusual symptoms while taking [MEDICINE_NAME].

Use Methylergometrine exactly as directed by your doctor. It is not a medicine for routine self‑use and should only be given under medical supervision, typically in a hospital or clinical setting.

• It is used immediately after childbirth to prevent or control postpartum haemorrhage (severe bleeding).

• It is administered only under medical supervision, typically in a hospital or clinical setting.

• Routes of administration include oral tablets, intramuscular injection, or intravenous injection, depending on urgency and the doctor’s judgment.

• It is not used during pregnancy before delivery, because its strong uterine contractions could harm the fetus.

• The dose and duration are short‑term and determined by the healthcare provider; it is not intended for long‑term use.

• Because it can raise blood pressure and cause vascular side effects, careful monitoring is required, especially in patients with hypertension or heart disease.

Methylergometrine works by binding to specific receptors (alpha-adrenergic, serotonergic, and dopaminergic) on the smooth muscle of the uterus. This binding triggers a series of biochemical reactions that lead to a sustained increase in the concentration of calcium within the muscle cells. The high calcium levels cause the muscle fibres to contract forcefully and stay contracted. These contractions put pressure on the uterine blood vessels, acting like a physical "plug" to stop bleeding.

• If you feel a sudden, severe headache or your vision becomes blurry, notify your doctor immediately as your blood pressure may be rising.

• Avoid smoking while taking this medication, as nicotine increases the vasoconstrictive effects of ergot alkaloids.

• If you are breastfeeding, it is often recommended to wait at least 12 hours after your last dose before nursing to minimize infant exposure.

Store Methylergometrine tablets at room temperature in a dry place away from light and moisture.

• Keep in the original container.

• The injection form must often be stored in a refrigerator (2°C to 8°C) in clinical settings.

• Keep out of the reach of children.

• Do not use after the expiry date.

• Grapefruit Juice (SEVERE): Can significantly increase the levels of Methylergometrine in the blood, increasing the risk of serious side effects like ergotism.

• General Diet: No other major food interactions are noted.

• CYP3A4 Inhibitors (SEVERE): Medications like clarithromycin, erythromycin, or certain antifungals can cause dangerous levels of Methylergometrine to build up.

• Triptans (CAUTION): Migraine medications like sumatriptan also constrict blood vessels; using them together increases the risk of heart or circulation issues.

• Beta-Blockers (CAUTION): May increase the vasoconstrictive effect, potentially leading to very high blood pressure.

• Hypertension (SEVERE): Should not be used in patients with high blood pressure or pre-eclampsia.

• Coronary Artery Disease (SEVERE): Risk of heart attack due to blood vessel constriction.

• Peripheral Vascular Disease (SEVERE): May worsen circulation issues in the limbs (Raynaud's).

• Sepsis (CAUTION): May increase the risk of ergotism.

Since Methylergometrine (Methergine) is given only by doctors or nurses in a hospital right after childbirth, overdose is very rare. The dose is carefully measured and monitored by the medical team. In the unlikely event that more than the intended amount is given, the womb may contract too strongly and blood pressure or circulation can be affected, sometimes causing headache, dizziness, chest discomfort, or tingling in the fingers and toes. Because it is administered under supervision, any such reaction is recognised quickly and managed immediately. With prompt care, recovery is usually good.

If you miss a dose of the tablets, take it as soon as you remember. If it is almost time for your next dose, skip the missed one. Do not take a double dose to compensate.